LRIT2: A Potential Drug Target and Biomarker (G340745)

Target Name: LRIT2

NCBI ID: G340745

LRIT2

Other Name(s): leucine-rich repeat, immunoglobulin-like and transmembrane domains 2 | Leucine rich repeat, Ig-like and transmembrane domains 2, transcript variant 2 | Leucine rich repeat containing 22 | leucine rich repeat containing 22 | leucine rich repeat, Ig-like and transmembrane domains 2 | Leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 2 precursor | Leucine-rich repeat-containing protein 22 | LRIT2_HUMAN | LRIT2 variant 2 | leucine-rich repeat-containing protein 22 | Leucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containing protein 2 | LRRC22

LRIT2: A Potential Drug Target and Biomarker

The protein LRIT2 (leucine-rich repeat, immunoglobulin-like and transmembrane domains 2) has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. LRIT2 is a member of the immunoglobulin-like module (Ig-like) and is expressed in a variety of tissues and cell types, including pluripotent stem cells, immune cells, and tissues.

The LRIT2 protein

LRIT2 is a 21-kDa transmembrane protein that is characterized by its leucine-rich repeat and immunoglobulin-like domains. The LRIT2 gene is located on chromosome 11q22 and has been shown to be expressed in various tissues, including the brain, pancreas, heart, kidneys, and liver. LRIT2 is also known to be involved in the regulation of cell signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway.

LRIT2 functions as a negative regulator of the TGF-β pathway

The TGF-β pathway is a critical signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. LRIT2 has been shown to function as a negative regulator of the TGF-β pathway, specifically in the regulation of TGF-β1 (transforming growth factor beta 1) activity. TGF-β1 is a potent growth factor that is involved in the development and maintenance of tissues and organs, and is a key regulator of cellular processes such as cell proliferation, differentiation, and survival.

LRIT2 has been shown to regulate the activity of TGF-β1 by interacting with its extracellular domain (ECD) and preventing TGF-β1 from binding to its cell surface. This interaction between TGF-β1 and LRIT2 has important implications for the regulation of cellular processes, including the regulation of cell growth, differentiation, and survival.

LRIT2 is also involved in the regulation of the NF-kappa-B pathway

The NF-kappa-B pathway is a signaling pathway that is involved in the regulation of inflammation, pain, and other cellular processes. LRIT2 is also shown to be involved in the regulation of the NF-kappa-B pathway, specifically in the regulation of NF-kappa-B2 (nuclear factor kappa B 2) activity. NF-kappa-B2 is a transcription factor that is involved in the regulation of various cellular processes, including inflammation, pain, and cell survival.

LRIT2 has been shown to regulate the activity of NF-kappa-B2 by interacting with its transmembrane domain and preventing NF-kappa-B2 from binding to its nuclear domain. This interaction between NF-kappa-B2 and LRIT2 has important implications for the regulation of cellular processes, including the regulation of inflammation, pain, and cell survival.

The potential clinical applications of LRIT2

The potential clinical applications of LRIT2 as a drug target or biomarker are numerous. LRIT2 has been shown to be involved in the regulation of cellular processes that are associated with a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, LRIT2 may be a useful target for the development of new therapeutic strategies for these diseases.

LRIT2 as a drug target

The potential clinical applications of LRIT2 as a drug target are numerous. LRIT2 has been shown to be involved in the regulation of cellular processes that are associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, LRIT2 may be a useful target for the development of new therapeutic strategies for these diseases.

LRIT2 as a biomarker

LRIT2 may also be

Protein Name: Leucine Rich Repeat, Ig-like And Transmembrane Domains 2

The "LRIT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRIT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets